EPS growth is an important number as it indicates the future prospects of Ekso Bionics. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but EPS has been 38.89% over the last twelve months. EPS growth is a vital measure of execution of the strategy for Ekso Bionics since it indicates how well the business is allocating resources to benefit shareholders.

Ekso Bionics is part of the medical instruments and equipment industry and is part of the healthcare sector. The company CEO is Jack Peurach. Ekso Bionics Inc designs, develops and sells wearable bionic human exoskeletons that have applications in healthcare, industrial, military, and consumer markets.

Previous Intraday Performance:

The EKSO shares had a previous change of 1.01% which opened at 2.00 and closed at 2.00. It moved to an intraday high of 2.07 and a low of 1.99.

SeekingAlpha:  AMD, BA, VALE among premarket gainers

Historical Performance:

Over the last five trading days, EKSO shares returned 3.09% and in the past 30 trading days it returned 52.67%. Over three months, it changed -5.21%. In one year it has changed 42.86% and within that year its 52-week high was 3.30 and its 52-week low was 1.23. EKSO stock is 62.60% above its 52 Week Low.

Our calculations result in a 200 day moving average of 1.92 and a 50 day moving average of 1.67. Right now, EKSO stock is trading 3.95% above its 200 day moving average and may be a good opportunity to buy.

SeekingAlpha:  Ekso Bionics up 35% on announcing JV in China


The company has a market cap of $125.3m with 62.6m shares outstanding and a float of 57.9m shares. Trading volume was 318,201 shares and has experienced an average volume of 529,682 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Ekso Bionics was -0.87 which ended on 31st of December 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.08.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.11
06-30-2018:  -0.13
03-31-2018:  -0.13
12-31-2017:  -0.15

Indicators Also to Watch:

Based on the latest filings, there is 7.80% of insider ownership and 40.60% of institutional ownership.

I calculated the beta to be 1.37

SeekingAlpha:  Ekso Bionics up 35% on announcing JV in China

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -180.62%, return on assets is -96.73%, price-to-sales is 15.49 and price-to-book is 22.20.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 3  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here